Illumina and Tempus AI Partner to Advance Precision Medicine with AI
Illumina Inc., a global leader in genomics, and Tempus AI, Inc., a prominent AI-driven precision medicine company, have announced a strategic collaboration to transform how next-generation sequencing (NGS) is adopted in clinical settings. By integrating Illumina’s advanced AI technologies with Tempus’s multimodal data platform, the partnership aims to accelerate the use of molecular profiling across a wide range of diseases, delivering on the promise of true precision medicine.
